Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

ConclusionPET/CT, performed already after administration of two ICIs ’ cycles, can identify the majority of non-responders in melanoma immunotherapy. In order to tackle however, the non-negligible phenomenon of pseudoprogression, another follow-up PET/CT, the usage of novel response criteria and vigilance over emergence of radiological irAEs are recommended. Moreov er, the investigation of spleen glucose metabolism may offer further prognostic information in melanoma patients under ICIs.
Source: EJNMMI Research - Category: Radiology Source Type: research